TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImmuPharma ( (GB:IMM) ) has shared an update.
ImmuPharma PLC has launched a new corporate website, highlighting its P140 autoimmune platform, which offers a novel approach to treating autoimmune diseases by restoring immune balance. The company is also developing a companion diagnostic tool for precise patient monitoring and is actively seeking partnerships to commercialize its P140 platform, with plans to complete a deal by the end of 2025. Financially, ImmuPharma has extended its cash runway into the second half of 2026 and aims to strengthen its cash position through potential partnerships.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
Average Trading Volume: 11,597,201
Technical Sentiment Signal: Buy
Current Market Cap: £60.83M
Learn more about IMM stock on TipRanks’ Stock Analysis page.